Published in J Neural Transm (Vienna) on February 04, 2008
Olfaction in Parkinson's disease and related disorders. Neurobiol Dis (2011) 1.51
Essential tremor and Parkinson's disease: lack of a link. Mov Disord (2011) 1.07
Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker? Ann Clin Transl Neurol (2014) 0.81
Cranial nerve I: olfaction. Psychiatry (Edgmont) (2009) 0.80
Transcranial sonography and the pocket smell test in the differential diagnosis between parkinson's disease and essential tremor. Neurol Sci (2015) 0.79
Essential tremor: is it a neurodegenerative disease? No. J Neural Transm (Vienna) (2012) 0.75
Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord (1998) 8.77
Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol (2004) 3.79
Essential tremor: clinical correlates in 350 patients. Neurology (1991) 2.89
Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology (1992) 2.36
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord (2000) 2.10
Dose-related effects of cigarette smoking on olfactory function. JAMA (1990) 1.94
Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry (2005) 1.83
The effect of ethanol on alcohol-responsive essential tremor: a positron emission tomography study. Ann Neurol (1996) 1.70
Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol (1995) 1.70
The relationship of essential tremor to other movement disorders: report on 678 patients. Essential Tremor Study Group. Ann Neurol (1994) 1.68
Rest tremor in patients with essential tremor: prevalence, clinical correlates, and electrophysiologic characteristics. Arch Neurol (2003) 1.59
[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 1.56
[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 1.51
Central mechanisms of tremor. J Clin Neurophysiol (1996) 1.43
Association between essential tremor and Parkinson's disease. Ann Neurol (1985) 1.33
Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol (2001) 1.32
Co-occurrence of essential tremor and Parkinson's disease: clinical study of a large kindred with autopsy findings. Parkinsonism Relat Disord (2003) 1.23
Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study. Arch Neurol (2005) 1.20
Animal models of tremor. Mov Disord (1999) 1.08
The pathophysiology of essential tremor. Neurology (2000) 1.06
Multiple oscillators are causing parkinsonian and essential tremor. Mov Disord (2000) 1.05
The role of reflexes in the resting tremor of Parkinson's disease. Brain (1986) 0.99
123I-IPT brain SPECT study in essential tremor and Parkinson's disease. Neurology (1999) 0.93
A prospective study of 50 cases of familial Parkinson's disease. Can J Neurol Sci (1983) 0.89
Olfaction in essential tremor patients with and without isolated rest tremor. Mov Disord (2003) 0.86
'Atypical' tremor. Eur Neurol (1995) 0.86
Significance of parkinsonian manifestations in essential tremor. Can J Neurol Sci (1993) 0.84
Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology (2007) 3.82
Assessment of sternal vascularity with single photon emission computed tomography after harvesting of the internal thoracic artery. J Thorac Cardiovasc Surg (1999) 2.24
Failure of aspirin treatment after stroke. Stroke (1994) 2.07
Camptocormia (bent spine) in patients with Parkinson's disease--characterization and possible pathogenesis of an unusual phenomenon. Mov Disord (1999) 1.94
Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease. Exp Neurol (2012) 1.91
Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology (2004) 1.84
Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology (2001) 1.83
Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol (1992) 1.61
Freezing of gait in patients with advanced Parkinson's disease. J Neural Transm (Vienna) (2001) 1.59
Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology (1995) 1.57
Evaluating dosage compensation on the chicken Z chromosome: should effective dosage compensation eliminate sexual bias? Heredity (Edinb) (2009) 1.55
Enhanced fatigue during motor performance in patients with Parkinson's disease. Neurology (1998) 1.53
Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology (1998) 1.41
Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet (1999) 1.40
Precursor control of neurotransmitter synthesis. Pharmacol Rev (1980) 1.34
Reduction in regional cerebral blood flow during normal aging in man. Stroke (1980) 1.34
Tardive dyskinesia associated with metoclopramide. Br Med J (1978) 1.33
Semaphorins as mediators of neuronal apoptosis. J Neurochem (1999) 1.31
Reactive hyperglycaemia in patients with acute stroke. J Neurol Sci (1976) 1.30
Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res (1980) 1.27
Increased plasma endothelin-1 in acute ischemic stroke. Stroke (1992) 1.26
Prevalence of Alzheimer's type dementia in an elderly Arab population. Eur J Neurol (2001) 1.23
Endoscopic transnasal transsphenoidal microsurgery versus the sublabial approach for the treatment of pituitary tumors: endonasal complications. Laryngoscope (1999) 1.23
Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol (1998) 1.20
Acute "upside down" reversal of vision in transient vertebrobasilar ischemia. Neurology (1987) 1.20
Effect of chronic atrial fibrillation on regional cerebral blood flow. Stroke (1980) 1.16
Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet (1979) 1.14
Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism. Neurology (1981) 1.11
Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc Natl Acad Sci U S A (1998) 1.11
Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci Lett (2001) 1.10
The prognostic value of the CT scan in conservatively treated patients with intracerebral hematoma. Stroke (1984) 1.09
Skin biopsy for assessment of autonomic denervation in Parkinson's disease. J Neural Transm (Vienna) (2006) 1.09
Paroxysmal dystonia as the initial manifestation of multiple sclerosis. Arch Neurol (1984) 1.08
Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett (2005) 1.06
Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol (1980) 1.05
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov Disord (2001) 1.05
Integral therapeutic potential of bone marrow mesenchymal stem cells. Curr Drug Targets (2005) 1.05
Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice. J Neurochem (1998) 1.05
Direct localisation of beta-adrenoceptor sites in rat cerebellum by a new fluorescent analogue of propranolol. Nature (1976) 1.04
Induction of neuronal apoptosis by Semaphorin3A-derived peptide. Brain Res Mol Brain Res (2000) 1.03
Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology (1996) 1.02
Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol (1979) 1.02
Hemiballismus: detection of focal hemorrhage in subthalamic nucleus by CT scan. Ann Neurol (1978) 1.02
Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy (2008) 1.01
Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest (1994) 1.00
Predictive value of balloon test occlusion of the internal carotid artery. Skull Base Surg (1995) 1.00
The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther (1981) 0.99
Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol (1996) 0.99
Diagnosis of "non-organic" limb paresis by a novel objective motor assessment: the quantitative Hoover's test. J Neurol (1998) 0.98
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res (2000) 0.98
Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA. Pharmacol Biochem Behav (1980) 0.97
Hemispheric brain damage in unilateral status epilepticus. Ann Neurol (1986) 0.97
Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1. J Biol Chem (2001) 0.97
Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons--a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett (1994) 0.97
Creutzfeldt-Jakob disease profile in patients homozygous for the PRNP E200K mutation. Ann Neurol (2000) 0.97
Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways. J Biol Chem (2001) 0.96
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol (2001) 0.96
Primary progressive freezing gait. Mov Disord (1993) 0.96
Reversible central nervous system dysfunction in folate deficiency. J Neurol Sci (1975) 0.96
The synthesis of prostaglandins by bovine cerebral microvessels. Prostaglandins Med (1980) 0.95
Capsular collagen staining of follicular thyroid neoplasms by picrosirius red: role in differential diagnosis. Acta Histochem (2001) 0.95
Stroke in Jerusalem district 1960 through 1967: an epidemiological study. Stroke (1973) 0.95
Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment. Neurology (1996) 0.94
Stimulation of nigrostriatal dopamine neurones by nicotine. Neuropharmacology (1982) 0.94
Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology (1986) 0.94
Mucus retention cyst of the maxillary sinus: the endoscopic approach. Br J Oral Maxillofac Surg (2000) 0.94
Chronic subdural hematoma simulating transient cerebral ischemic attacks. Case report. J Neurosurg (1975) 0.93
Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm (Vienna) (2000) 0.92
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. Isr J Med Sci (1996) 0.92
Regional cerebral blood flow in patients with Parkinson's disease. Arch Neurol (1979) 0.91
Progressive brain atrophy during normal aging in man: a quantitative computerized tomography study. Isr J Med Sci (1985) 0.91
Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm (Vienna) (2001) 0.90
Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism. Neurology (1984) 0.90
The Tel Aviv Stroke Registry. 3600 consecutive patients. Stroke (1996) 0.90
ACE, MTHFR, factor V Leiden, and APOE polymorphisms in patients with vascular and Alzheimer's dementia. Stroke (1998) 0.90
Spinal dural arteriovenous fistulae--a diagnostic challenge. Isr Med Assoc J (2001) 0.90
Anterior horn of the lateral meniscus: another potential pitfall in MR imaging of the knee. Radiology (1997) 0.89
Dopamine-induced programmed cell death in mouse thymocytes. Biochim Biophys Acta (1995) 0.89
Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord (1999) 0.89
The effect of acute stroke on cardiac functions as observed in an intensive stroke care unit. Stroke (1975) 0.88
Cortical blindness as a manifestation of basilar artery occlusion. Eur Neurol (1974) 0.88
The assessment of changes in brain volume using combined linear measurements. A CT-scan study. Neuroradiology (1984) 0.88
Histological changes in the cervical lymph nodes after radiotherapy. Oncol Rep (2001) 0.87
Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology (1985) 0.87
Hypertension and diabetes as risk factors in stroke patients. Stroke (1974) 0.87
Abnormal skin wrinkling in the less affected side in hemiparkinsonism-a possible test for sympathetic dysfunction in Parkinson's disease. Biomed Pharmacother (2001) 0.87
Early-occurrence of manual motor blocks in Parkinson's disease: a quantitative assessment. Acta Neurol Scand (1999) 0.87
Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J Neurochem (2001) 0.87
6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell Mol Neurobiol (2001) 0.87
Machado-Joseph (Azorean) disease in a Yemenite Jewish family in Israel. Neurology (1994) 0.87
The regional cerebral blood flow in patients under chronic hemodialytic treatment. J Cereb Blood Flow Metab (1987) 0.86
Clinical characterization of genetic hearing loss caused by a mutation in the POU4F3 transcription factor. Arch Otolaryngol Head Neck Surg (2000) 0.86
Late-onset progressive radiculomyelopathy in patients with cervical athetoid-dystonic cerebral palsy. Eur Neurol (1987) 0.86
Sudden hearing loss as a presenting symptom of acoustic neuroma. Am J Otolaryngol (1999) 0.86
Annexin V SPECT imaging of phosphatidylserine expression in patients with dementia. Neurology (2006) 0.86
The molecular mechanism of dopamine-induced apoptosis: identification and characterization of genes that mediate dopamine toxicity. J Neural Transm Suppl (2000) 0.86
Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease. J Neural Transm Suppl (2007) 0.86